Dendritic cell biology and its role in tumor immunotherapy.

Wang Y, Xiang Y, Xin VW, Wang XW, Peng XC, Liu XQ, Wang D, Li N, Cheng JT, Lyv YN, Cui SZ, Ma Z, Zhang Q, Xin HW. · 2020

Read Dendritic cell biology and its role in tumor immunotherapy. by Wang Y, Xiang Y, Xin VW, Wang XW, Peng XC, Liu XQ, Wang D, Li N, Cheng JT, Lyv YN, Cui SZ, Ma Z, Zhang Q, Xin HW. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7397618.txt.

Introduction

Wang and co-authors review dendritic cell biology and cancer immunotherapy in the Journal of Hematology and Oncology. Dendritic cells are the immune system's chief presenters, showing captured material to T cells to launch attacks. That makes them natural tools and targets for tumor treatment.

The review explains how these cells grab antigens through several routes, cut them into peptides, and display them to CD4 and CD8 T cells. Newer findings include dendritic cell exosomes joining presentation, hyperactive cells that turn effectors into memory cells, and cross-talk with natural killer cells. Inside tumors, the cells act as sentinels of surveillance. The authors then survey dendritic cell therapies in preclinical and clinical work. Readers get a full picture of a pivotal cell.

Catalog record

CREATORWang Y, Xiang Y, Xin VW, Wang XW, Peng XC, Liu XQ, Wang D, Li N, Cheng JT, Lyv YN, Cui SZ, Ma Z, Zhang Q, Xin HW.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE84 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7397618

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Dendritic cell biology and its role in tumor immunotherapy By Yingying Wang, Ying Xiang, Victoria W Xin, Xian-Wang Wang, Xiao-Chun Peng, Xiao-Qin Liu, Dong Wang, Na Li, Jun-Ting Cheng, Yan-Ning Lyv, Shu-Zhong Cui, Zhaowu Ma Published in: Journal of Hematology & Oncology DOI: 10.1186/s13045-020-00939-6 ABSTRACT Abstract As crucial antigen presenting cells, dendritic cells (DCs) play a vital role in tumor immunotherapy. Taking into account the many recent advances in DC biology, we discuss how DCs (1) recognize pathogenic antigens with pattern recognition receptors through specific phagocytosis and through non-specific micropinocytosis, (2) process antigens into small peptides with proper sizes and sequences, and (3) present MHC-peptides to CD4+ and CD8+ T cells to initiate immune responses against invading microbes and aberrant host cells. During anti-tumor immune responses, DC-derived exosomes were discovered to participate in antigen presentation. T cell microvillar dynamics and TCR conformational changes were demonstrated upon DC antigen presentation. Caspase-11-driven hyperactive DCs were recently reported to convert effectors into memory T cells. DCs were also reported to crosstalk with NK cells. Additionally, DCs are the most important sentinel cells for immune surveillance in the tumor microenvironment. Alongside DC biology, we review the latest developments for DC-based tumor immunotherapy in preclinical studies and clinical trials. Personalized DC vaccine-induced T cell immunity, which targets tumor-specific antigens, has been demonstrated to be a promising form of tumor immunotherapy in patients with melanoma. Importantly, allogeneic-IgG-loaded and HLA-restricted neoantigen DC vaccines were discovered to have robust anti-tumor effects in mice. Our comprehensive review of DC biology and its role in tumor immunotherapy aids in the understanding of DCs as the mentors of T cells and as novel tumor immunotherapy cells with immense potential. Keywords: Dendritic cells (DCs), MHC, Immune cells, Tumor immunotherapy INTRODUCTION Antigen presenting cells (APCs) play a significant role in both innate and adapted immunity responses. The category of APCs consists of macrophages, dendritic cells (DCs), and B lymphocytes [1]. DCs, first discovered by Ralph Steinman in 1973, are the most important of the APCs and have many different subtypes. These subtypes have a variety of special functions in immunological processes, such as initiating immune reactions, regulating immune responses, and maintaining those responses [2]. According to its ontogeny, a DC can be categorized as either a conventional DC (cDC) or a plasmacytoid DC (pDC), as summarized in Table 1 [3]. Also, according to the developmental stage of the DC, it can be classified into two major categories: immature and mature [4]. Most immature DCs reside on mucosal surfaces, with the skin and solid organs acting as sentinels to recognize antigens. These DCs have a lower expression of major histocompatibility complex (MHC) I and MHC II, T cell co-stimulation factors, and adhesion molecules [3]. Immature DCs do not secrete proinflammatory cytokines. However, they are capable of migration. [Table: DC classification] When immature DCs uptake antigens, they shift to secondary lymphoid organs and present antigens to helper T cells or effector T cells to trigger specific cytotoxic T lymphocyte (CTL) responses [5]. In the meantime, they also gradually become more motile and upregulate the expression of CC-chemokine receptors 7, 8 (CCR7, 8) [6]. On the other hand, matured DCs have a reduced ability to uptake and process antigens but have an enhanced migration capacity. In addition, mature DCs were also reported to have an increased expression of various co-stimulatory molecules—for instance, CD40, CD70, and CD80, as well as CD86—and an increased production of proinflammatory cytokines and chemokines [7, 8]. Here, we review the latest studies on DCs as the mentors of T cells, with an emphasis on how DCs specifically recognize, process, and present antigens to program T cells for immune activation, suppression, or memorization. We also highlight some recent developments that demonstrate the immense potential of DCs in tumor immunotherapy. ANTIGEN RECOGNITION AND INTERNALIZATION DCs are highly dynamic, using their specific receptors to recognize foreign invading antigens or aberrant self-antigens. DCs recognize antigens through pathogen-associated molecular patterns (PAMPs) as well as danger-associated molecular patterns (DAMPs) through pattern recognition receptors (PRRs). DCs then uptake, process, and present antigens to T cells to initiate immune responses (Fig. 1a). [Figure: Pathways of antigen recognition, processing, and presentation of DCs. a Antigen recognition and internalization into the early endosome through specific phagocytosis (microautophagy and chaperone-mediated autophagy) or non-specific macropinocytosis. b Dimers of MHC-I and MHC-II are formed in the endoplasmic reticulum (ER). MHC-II binds with a non-polymorphic invariant chain Ii (CD 74). c Gradual acidification to approximate pH 3.8–5.0 by the ATP-dependent vacuolar proton pump, increasing the lysosomal enzyme activity in the late endosomal and lysosomal-processing compartments. After proteolytic cleavage, antigens are transferred to MHC molecules. d MHC-I antigen cross-presentation involved in modulating receptor-mediated signaling. e MHC-II antigen presentation involved in modulating receptor-mediated signaling] Specific phagocytosis The critical approach of antigen uptake by DCs and other immune cells is generally believed to be phagocytosis [7]. There are two important forms of phagocytosis: microautophagy and chaperone-mediated autophagy (Fig. 1a). Microautophagy is initiated when the expression of master regulator RAB5A is altered and the MHC-II compartment (MIIC) is fused by the autophagy protein LC3. As a key endocytic protein, the master regulator RAB5A also has multiple physiological activities, such as promoting coherent and ballistic collective motility, impacting junctional mechanics and monolayer rigidity, and increasing endomembrane trafficking [9]. Chaperones, such as C-type lectins and Fc receptors, can recognize antigens by targeting special ligands of apoptotic cells or pathogens. Afterwards, the endocytosis process, mediated by clathrin, is induced, which places antigens into antigen-processing compartments [10]. Here, we have highlighted the major mechanisms of chaperone-mediated autophagy. C-type lectin receptors (CLRs) Pattern-recognition receptors are critical components to immune responses. They recognize invading microbes and induce protective immune responses to infection. CLRs, a type of pattern-recognition receptor, are central to antifungal immunity. They are expressed on macrophages as well as DCs. Dectin-1, CLEC9, and DEC-205 (lymphocyte antigen 75) are all examples of CLRs [10]. Specifically, the calcium-dependent carbohydrate recognition domains (CRD) in CLRs recognize conserved fungal cell-wall carbohydrates and their glycosylation pattern, also known as the carbohydrate fingerprint [11]. The melanin-sensing C-type lectin receptor MelLec plays a major role in antifungal immunity by recognizing naphthalene-diol of 1,8-dihydroxynaphthalene (DHN)-melanin. MelLec has the ability to identify the conidial spores of Aspergillus fumigatus and other DHN-melanized fungi [12, 13]. The C-Type lectin 5A (CLEC5A) is a spleen tyrosine kinase (Syk)-coupled receptor of APC and plays a pivotal role in the activation of innate immunity against viruses—especially Flavivirus [14]. CLEC5A promotes neutrophil extracellular trap development and the production of both reactive oxygen species and proinflammatory cytokines by recognizing the bacteria Listeria monocytogenes. It can also induce inflammasome activation in macrophages and stimulate the immune reaction of T cells [14]. The human DC-specific intercellular adhesion molecule-1 grabbing nonintegrin (DC-SIGN or CD209) is thought to be a canonical of the C-type lectin receptor expressed on both macrophages and DCs [15]. It is a type 2, mannose-specific C-type lectin that also works as a cytosolic DNA-sensor. It induces specific immune responses upon the recognition of glycans through its carbohydrate recognition domains (CRD) [16, 17]. After DC-SIGN recognizes fucose-based PAMPs, it activates IKKε. In turn, IL-27 is produced, follicular T helper cell (TFH) differentiation is facilitated, B cell IgG production is stimulated, B

Read the complete text